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influx through the mitochondrial pyruvate carrier) was calculated to be 21, close to upper limit of oxidative metabolism.

Cancer cells exhibit metabolic patterns that differ significantly from those of terminally differentiated adult tissues.
They require rapid production of both energy and biosynthetic
precursors to sustain a high rate of proliferation. The network
of biochemical pathways underlying these processes is complex. Most of the individual enzymatic conversions involved in
this network have probably already been identified, but a comprehensive and quantitative description of the fluxes involved is
lacking. Methods to produce such descriptions will likely be
very useful in the design of new therapeutics that specifically
target the metabolic abnormalities of cancer as well as in clinical implementation of non-invasive methods for detection of
cancer and its therapeutic response.
The kinetics of 13C isotope labeling as monitored by NMR
spectroscopy has been used to measure flux through various
metabolic pathways of perfused isolated cells and organs and in
vivo (1– 4). Kinetic data provide estimates of absolute flux,
whereas steady-state data measure relative flux. Both types of
analysis require validated mathematical models, which have
been formulated for the heart (5–10), liver (11–13), brain (14 –
16), and tumors (17). Only the heart model has been validated
by comparison between model-derived and experimental
parameters (6, 7). Modeling of tumor metabolic fluxes has been
limited to steady-state analysis with dynamic measurements of
glucose uptake and lactate production subsequently added to
convert to absolute fluxes; none of these models has been validated. To the best of our knowledge, this is the first validated
dynamic flux model of tumor intermediary metabolism based
on 13C NMR isotope kinetic data.
Mathematical models of 13C magnetic resonance spectroscopy data are based on measurement of positional isotopic
enrichment and/or on isotopomer analysis, which takes into
account spin-spin coupling of covalently bonded labeled carbon
atoms. Bonded cumomer analysis includes both positional enrichment and isotopomer modeling and facilitates the formulation of
kinetic differential equations. This method requires fewer equations than classical isotopomer analysis and is based on internal
symmetry properties of metabolite isotopomers.
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A network model for the determination of tumor metabolic
fluxes from 13C NMR kinetic isotopomer data has been developed and validated with perfused human DB-1 melanoma cells
carrying the BRAF V600E mutation, which promotes oxidative
metabolism. The model generated in the bonded cumomer formalism describes key pathways of tumor intermediary metabolism and yields dynamic curves for positional isotopic enrichment and spin-spin multiplets. Cells attached to microcarrier
beads were perfused with 26 mM [1,6-13C2]glucose under normoxic conditions at 37 °C and monitored by 13C NMR spectroscopy. Excellent agreement between model-predicted and experimentally measured values of the rates of oxygen and glucose
consumption, lactate production, and glutamate pool size validated the model. ATP production by glycolytic and oxidative
metabolism were compared under hyperglycemic normoxic
conditions; 51% of the energy came from oxidative phosphorylation and 49% came from glycolysis. Even though the rate of
glutamine uptake was ⬃50% of the tricarboxylic acid cycle flux,
the rate of ATP production from glutamine was essentially zero
(no glutaminolysis). De novo fatty acid production was ⬃6% of
the tricarboxylic acid cycle flux. The oxidative pentose phosphate pathway flux was 3.6% of glycolysis, and three non-oxidative pentose phosphate pathway exchange fluxes were calculated. Mass spectrometry was then used to compare fluxes
through various pathways under hyperglycemic (26 mM) and
euglycemic (5 mM) conditions. Under euglycemic conditions
glutamine uptake doubled, but ATP production from glutamine
did not significantly change. A new parameter measuring the
Warburg effect (the ratio of lactate production flux to pyruvate

Cumomer Analysis of Cancer Cell Metabolism

Experimental Procedures
Cell Culture—DB-1 human melanoma cells were derived
from a lymph node metastasis (Thomas Jefferson University
Hospital, Philadelphia, PA). The cells were obtained before
administration of any treatment. Cells were cultured from the
tumor and cryopreserved after the 16th passage. The presence
of melanoma cell surface antigens was confirmed with monoclonal antibodies (25). For routine culture, DB-1 cells were
grown as monolayers at 37 °C in 5% CO2 in ␣-minimal essential
medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 26 mM glucose, and 1% (v/v) non-essential amino acids
and 10 mM HEPES buffer. The doubling time in tissue culture
flasks was 48 h (26).
Cell Perfusion and NMR Spectroscopy—For cell perfusion
studies, DB-1 cells were cultured in DMEM with 1% (v/v) nonessential amino acids (Invitrogen), 10% fetal bovine serum, 10

3

The abbreviations used are: BC, bonded cumomer; TCA cycle, tricarboxylic
acid cycle; PPP, pentose phosphate pathway; MRO2, O2 consumption rate;
GLUT, glucose transporter; MCT, monocarboxylic acid transporter; FA, fatty
acid; MID, mass isotopomer distribution; G3P, glyceraldehyde 3-phosphate; 6PG, D-6-phosphogluconate; Ru5P, D-ribulose 5-phosphate; R5P,
D-ribose 5-phosphate; X5P, D-xylulose 5-phosphate; S7P, D-sedoheptulose
7-phosphate; E4P, D-erythrose 4-phosphate; PDH, pyruvate dehydrogenase; MDH, malate dehydrogenase; SDH, succinate dehydrogenase; ADM,
atom distribution matrix; GLS, glutaminase.
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mM HEPES, 4 mM glutamine, and 26 mM glucose (complete
DMEM). During NMR experiments, ⬃5 ⫻ 108 cells were grown
on the surface of non-porous microcarriers that had a mean
diameter of 170 m (SoloHill, Ann Arbor, MI). The surface of
the microcarriers was coated with either collagen or ProNectinF威 to enhance cell attachment and proliferation. The microcarriers were tightly packed inside a 20-mm NMR tube. They
were perfused continuously with the system shown in Fig. 1A. A
detailed description of the perfusion system, including flow
rates, cell adhesion procedures, etc., has been presented previously (20).
A peristaltic pump (Masterflex, Cole Parmer, Chicago) was
used to circulate medium through the microcarriers at a flow
rate of 12 ml/min. Before entering the cell mass, the medium
flowed through a gas exchange module where carbon dioxide
was removed, and oxygen was added across a silicone membrane (thin-wall silicone tubing). Subsequently, the medium
was warmed to 40 °C, and the oxygen level was measured continuously with a polarographic oxygen probe (Mettler-Toledo,
Columbus, OH). The steady-state oxygen level of the medium
at the inlet of the cell mass was maintained near air saturation.
A second polarographic oxygen probe was used to detect the
oxygen level of the medium coming out of the NMR tube so that
the oxygen consumption rate of the culture could be determined continuously. A pH probe (Mettler-Toledo, Columbus,
OH) was also used downstream of the outlet oxygen probe. The
pH of the medium was controlled by adjusting the level of CO2
in the gas exchange module. The temperature of the medium
entering the NMR tube was fine-tuned with a microstat-controller and an electrical resistance heater to 37 ⫾ 0.2 °C. The
glucose concentration in the recirculating medium was maintained at a constant level (clamped) by continuously feeding
fresh medium and removing depleted medium from a recirculation bottle. The flow rate of fresh medium to the system was
typically 24 ml/h, and the volume of recirculating medium was
120 ml. During the 13C experiments, 32 mM [1,6-13C2]glucose
was introduced into the feed to the system, and the recirculating glucose level was clamped at 26 mM by adjusting the feed
rate.
13
C NMR spectra were acquired with standard 1H decoupled
NOE 13C acquisition on a 9.4 tesla/89 mm vertical bore Varian
spectrometer (Varian Inc., Palo Alto, CA). The acquisition
parameters were as follows: 60° pulse angle, 1.2-s repetition
rate, 25,000 Hz spectral width, 16,384 points, and 750 transients
per spectrum. To ensure that 1H decoupling did not raise the
temperature of the perfusate above 37.5 °C, the temperature of
the medium leaving the NMR tube was continuously monitored with a thermocouple. Free induction decays were apodized by exponential multiplication (2 Hz) for signal to noise
enhancement. Nuts NMR (Acorn NMR, Fremont, CA) was
used to determine resonance peak areas. The cell number in the
NMR tube was determined from the total NTP level as
described previously (27). 31P spectral parameters were 60°
pulse angle, 1-s repetition rate, 15,000 Hz, and 1200 transients.
In this work, melanoma cells were initially studied under
normoxic hyperglycemic conditions to enhance lactic acidosis
(28, 29) and subsequently under euglycemic conditions to more
closely simulate in vivo conditions. The effects of glucose conVOLUME 291 • NUMBER 10 • MARCH 4, 2016
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Our laboratories have developed a Continuous Stirred Tank
Bioreactor suitable for high resolution 13C NMR spectroscopy
of cultured cancer cells that can produce detailed spectra with
good temporal resolution while simultaneously monitoring the
oxygen consumption rate (18 –21). Specifically, we measured
the time course for labeling of key intermediates such as glutamate, aspartate, alanine, lactate, and fatty acyl groups in real
time during growth with 13C-labeled glucose and unlabeled
glutamine as substrates.
Here, we demonstrate that absolute flux measurements of
perfused tumor cells can be obtained in several hours from
⬃5 ⫻ 108 tumor cells in this bioreactor system, and the data can
be analyzed using a refined isotopomer analysis method called
bonded cumomer (BC)3 analysis (22) that utilizes only ⬃210
differential equations to describe most of tumor intermediary
metabolism, whereas the heart model of Chance et al. (5)
required ⬃325 differential equations to describe just TCA cycle
activity in terms of positional enrichment. To validate the BC
model, we compared model-derived and experimental values of
the following parameters: O2 consumption rate (MRO2), glutamate pool sizes, as well as rates of glucose consumption and
lactate release. This study permits direct measurements of
energy production by glycolytic and mitochondrial pathways
and quantitative evaluation of the Warburg effect. It also provides a basis for future studies of the effects of various therapeutic interventions on tumor metabolism. Whereas studies of
perfused tumor cells in a bioreactor facilitate accurate and
reproducible measurements, this model is also applicable to in
vivo studies in animal models and humans. Recent studies of ex
vivo surgically resected human brain (23) and lung (24) tumors
point to the potential utility of in vivo 13C MRS clinical
applications.

Cumomer Analysis of Cancer Cell Metabolism
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in the negative ion mode. The injection volume was 10 l. Analytes were separated by reverse-phase ion-pairing chromatography utilizing a Phenomenex Luna C18 column (150 ⫻ 2.00
mm, 3 m particle size) at a flow rate of 200 l/min and maintained at 45 °C. A two-gradient solvent system was used, with
solvent A as 400 mM 1,1,1,3,3,3-hexafluoro-2-propanol and 10
mM diisopropylethylamine in water, and solvent B as 400 mM
1,1,1,3,3,3-hexafluoro-2-propanol and 10 mM diisopropylethylamine in methanol. The linear gradient conditions were as follows: 2% B at 0 min; 2% B at 4 min; 95% B at 9 min; 95% B at 11
min; and 2% B at 11.5 min, followed by a 3.5-min equilibration.
The Agilent 6460 mass spectrometer operating conditions were as
follows: gas temperature was set at 320 °C, and the gas flow was set
to 8 liters/min. The sheath gas temperature was 400 °C, and the
sheath gas flow was set to 10 liters/min. The capillary voltage was
set to 3000 V, and the nozzle voltage was set to 1000 V.
Bonded Cumomer Metabolic Network Model—To calculate
fluxes through key pathways of tumor energy metabolism from
13
C isotopic labeling data, we have utilized a novel three-compartment metabolic network model with the bionetwork schematically depicted in Fig. 2 and applicable to Continuous
Stirred Tank Bioreactor systems. The model includes medium,
cytosolic and mitochondrial compartments interconnected
with various transporters. The cytosolic membrane contains
glucose (GLUT), monocarboxylic acid (MCT), and glutamine
(GLN) transporters to the cytosolic compartment. Tumors
generally express GLUT1 and GLUT3, but only GLUT1 is currently included in the model; similarly DB-1 contains MCT1
and MCT4 in approximately equal proportions (26), but
because the Km value of MCT1 is ⬃1/10th that of MCT4, we
have only included MCT1 in the current model. We have
included the GLN transporter (alanine-serine-cysteine (GLN)
transporter 2) because of the critical role of glutamine in tumor
energetics and metabolism. The BC model can readily be
extended to incorporate other isoforms of MCT and GLUT as
well as transporters for other amino acids and metabolites.
The mitochondrial pyruvate carrier, which was recently
identified in all mammalian cells (31–33), was included to permit access of pyruvate to the PDH complex for conversion to
acetyl-CoA and incorporation into the TCA cycle. Pyruvate is
also linked to the TCA cycle via pyruvate carboxylase. Citrate,
glutamate, and malate are included in the cytosolic compartment with direct links through the mitochondria to the TCA
cycle. As already noted, the mitochondrial compartment contains the complete TCA cycle with links to the cytosol for citrate and malate. ␣-Ketoglutarate is linked to glutamate via glutamate dehydrogenase (GLUD) and two aminotransferases,
aspartate aminotransferase (GOT) and alanine aminotransferase (GPT).
A constructed BC dynamic model adapted to perfusion bioreactor experiments was used to fit the 13C time courses of
labeled lactate, glutamate, and fatty acids to determine the corresponding metabolic fluxes and the transport parameter for
bidirectional lactate transport through the cell membrane. In
the model, the perfused [1,6-13C2]glucose and glutamine
(labeled in some experiments, see below) are transported from
the extracellular medium to the DB-1 cells assuming that
reversible non-steady-state Michaelis-Menten facilitative
JOURNAL OF BIOLOGICAL CHEMISTRY
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centration on flux through various pathways of tumor metabolism were evaluated. In the initial studies, the concentration of
glucose in the perfusate was maintained at 26 mM, a value that
we believe would be the upper limit for a therapeutic procedure.
In subsequent studies, the glucose concentration was 5 mM.
The kinetics of labeling in lactate, glutamate, and other metabolites was monitored over an ⬃6-h time course. The results
were used to estimate intracellular fluxes. The estimated TCA
cycle flux was compared with the oxygen consumption flux to
test the accuracy of the calculations.
Pentose Phosphate Pathway (PPP) Labeling—DB-1 cells were
grown in T-150 flasks in ␣-minimal essential medium. At about
70% confluency of cells in the flask, the medium was replaced
with DMEM with 5 mM [1,2-13C]glucose (Cambridge Isotope
Laboratories, Inc., Cambridge, MA) and incubated for 8 h at
37 °C and 5% CO2. The cells were harvested by using 0.05%
trypsin/EDTA (Invitrogen), rinsed twice with phosphate-buffered saline (PBS) at 4 °C, and frozen. The cells were homogenized after adding 4 ml of 12 M perchloric acid and were
spun at 13,000 ⫻ g for 30 min. The supernatant was neutralized
with 3 M KOH, lyophilized, and dissolved in 0.6 ml of D2O. High
resolution NMR spectra of the metabolites were generated
using a 9.4-tesla spectrometer (Agilent, Palo Alto, CA)
equipped with a 5-mm broadband probe. Proton-decoupled
13
C spectra were acquired with the following parameters:
sweep width ⫽ 20 kHz, number of points ⫽ 128,000, flip angle
30°, repetition time ⫽ 7.3 s, and number of average ⫽ 7000. The
proton-observed carbon-edited NMR technique (30) was
employed to differentiate between the 13C-labeled and -unlabeled lactate signals in the proton spectra with the following
parameters: sweep width ⫽ 5 kHz, number of points ⫽ 32,000,
repetition time ⫽ 12 s, echo time ⫽ 1/J ⫽ 7.8 ms, and number of
average ⫽ 64. Experiments were run in duplicate. iNMR software (Mestrelab Research, Spain) was used for spectral fitting
and integration.
Glutaminolysis and Fatty Acids Labeling—DB-1 cells were
grown on C104-1521 microcarriers (SoloHill) in uncoated T-75
flasks with ␣-minimal essential medium. At about 70% confluency of cells on the microcarrier beads, the medium was
replaced with DMEM with 2 mM L-glutamine (U-13C5, 99%)
(Cambridge Isotope Laboratories, Inc.). Two concentrations of
glucose were used in the medium, 5 and 25 mM. After 8 h of
incubation, the cells were carefully stripped from the microcarriers using mechanical agitation. Microcarriers were allowed to
settle, and suspension containing cells was collected. Cells were
rinsed twice with PBS at 4 °C and frozen until metabolite
extraction. For fatty acid labeling, cells were grown, incubated,
and harvested as above with the exception that the incubation
was performed for 24 h and the label used was L-glutamine
(13C5, 99%; 15N2, 99%) (Cambridge Isotope Laboratories, Inc.).
LC/MS—The isotope-enriched cells were washed twice with
PBS and resuspended in 700 l of ice-cold methanol. Samples
were pulse-sonicated for 30 s and centrifuged at 16,000 ⫻ g for
10 min. The supernatant was then transferred to another tube
and evaporated to dryness under nitrogen. Samples were resuspended in 100 l of water and analyzed using an Agilent 1200
series HPLC system coupled to an Agilent 6460 triple quadrupole mass spectrometer equipped with an ESI source operated

Cumomer Analysis of Cancer Cell Metabolism
transport kinetics occurs through glucose (GLUT family) or
glutamine (alanine-serine-cysteine (GLN) transporter 2) transporters as shown in Equation 1,

冉

冊

Mei Mi
tr ⫺ tr
Kmi
Kmi
tr
Ji ⫽
Mei Mi
1 ⫹ tr ⫹ tr
Kmi Kmi
J trmax

(Eq. 1)

关M兴

冘v F ⫺冘v F
pj pj
i i

j

uk uk
i
i

(Eq. 2)

k

where Mi is intracellular concentration of the i species; Jitr is net
transport flux for boundary species i between media and cytosol
or cytosol and mitochondria; Fipj and Fiuk are normalized reaction fluxes that produce (j) or utilize (k) cellular species i; and vipj
and iuk are corresponding stoichiometric coefficients. For
extracellular boundary metabolites in the medium, dynamic
mass balance has the following general form as shown in Equation 3,
dMe
⫽ rie 䡠 Jitr
dt

(Eq. 3)

where the extracellular species concentration is Me, and rie is
the ratio of cell volume to media volume. An additional term for
the medium flow rate was also was included. Note that we do
not assume here that media boundary metabolites are at constant concentrations, and this assumption (or lack of assumption) is common for bioreactor systems.
Together with the initial metabolome state vector M0 ⑀ RN
and fluxome Fo ⑀ RM (subscript 0 refers to baseline steady-state
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where metabolite M is downstream of another metabolite Sj.
The total outflux 冱Fk balances total influx 冱Fj. [M] represents
the total pool size of metabolite M, whereas (i) and j(i) represent the ith cumomer fraction of metabolite M and metabolite Sj (i bonded cumomer), respectively.
Isotopomer balance equations were derived for every metabolite bonded cumomer of orders 1, 2, and 3 (e.g. glutamate,
glutamine, and aspartate) as described by Shestov et al. (22).
This resulted in a set of ⬃210 differential equations. Fine structure multiplets were completely described by each metabolite’s
bonded cumomers of order 1, 2, and 3. The use of bonded
cumomers leads to a reduced number of equations compared
with a model, including all possible isotopomers, while retaining all the NMR-measurable isotopomer information. The term
cumomer was first proposed by Wiechert et al. (34), and the
concept of cumomer was used in early studies by Muzykantov
and Shestov (35). There are connection matrices between the
“bonded cumomer”  vectors, which reflect subsets of particularly labeled isotopomers and the vectors of singlets, doublets,
triplets, and quartets of metabolite “fine structure” of 13C NMR
spectra. One can derive kinetic equations in the form of finestructure spectroscopically defined NMR data using matrix
connection equations. For example, for a metabolite with five
carbon atoms such as glutamate, the equation for carbon 2
would be as shown in Equation 5,

冢 冣冢
c 2q
c 2d12
c 2d23
c 2s

⫽

0
0
0
1
0
1
0 ⫺1
0
0
1 ⫺1
1 ⫺1 ⫺1
1

冣冢 冣
䡠

c2
c12
c23
c123

(Eq. 5)

For [1,6-13C2]glucose perfusion, the fitted time courses were
as follows: Glu4Tot (Tot-total), Glu4s, Glu4d34, Glu3Tot,
Glu3d, Glu2Tot, Glu2s, Lac3Tot, and acylmethylene (–(CH2)n–)
resonance, for a total of nine curves. The following free fluxes
were determined: melanoma TCA cycle FTCA; pyruvate carboxylase FPC; exchange between glutamate and ␣-ketoglutarate FX;
anaplerotic exchange and net flux at the level of succinyl-CoA;
FANA; mitochondrial malic enzyme (ME2 ⫹ ME3) activity; de
novo fatty acid production, glutaminolysis, aspartate efflux; and
three other parameters, Michaelis-Menten lactate transport
VmaxLAC, and KmLAC, and total cellular lactate concentration.
Other fluxes and parameters, including the Warburg effect
value, were calculated based on flux balance analysis, including
non-oxidative glycolytic flux CMRlac and others. Solving a system of differential equations (using the Runge-Kutta 4th order
procedure for stiff systems) in terms of bonded cumomer variables yields time courses for all possible fine structure 13C multiplets of glutamate, glutamine, and aspartate.
VOLUME 291 • NUMBER 10 • MARCH 4, 2016
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where Jitr is the net transport flux for boundary species i
between media and cytosol or cytosol and mitochondria; Mei
max
is the extracellular concentration for species i; Jtr
is the
tr
maximal transport rate; Kmir is the Michaelis-Menten constant
for transport. The labeled lactate from the cell is transported
into the medium and obeys the same Michaelis-Menten kinetics through the mono-carboxylic acid transporter (MCT family). In this study, facilitated media-cell transport is assumed for
glucose, lactate, and glutamine.
The metabolic network includes glycolysis, TCA cycle, ␣ketoglutarate-glutamate, and oxaloacetate-aspartate exchange
through the following: malate-aspartate shuttle; anaplerosis
through (a) pyruvate carboxylase activity, (b) at the succinylCoA level, and (c) glutaminolysis through mitochondrial
glutaminases (GLS and GLS2); pyruvate recycling through
cytosolic (NADP⫹-dependent ME1) and mitochondrial malic
enzymes (NAD⫹-dependent ME2 and NADP⫹-dependent
ME3); lactate dehydrogenase activity; and transport processes.
In this study, PPP fluxes through oxidative and non-oxidative
branches were included in the modeling analysis. The network
also includes de novo lipogenesis and fatty acid oxidation.
The model was expressed mathematically using two types of
mass balance equations, i.e. for chemical and isotope variables.
The mass balance equation for the total metabolite concentration in the medium, cytosol and mitochondria is Equation 2,
dMi
⫽ Jitr ⫹
dt

values and reaction rates) isotopomer dynamics of this system
are formulated as an initial value problem for ordinary differential equations in terms of bonded cumomer fractions as the
state variables. For parallel monomolecular reactions, metabolite 13C cumomer mass balance was expressed in the form
shown in Equation 4,

Cumomer Analysis of Cancer Cell Metabolism

In this matrix the symbol “1” reflects a particular carbon
transfer from substrates (the upper level of the matrix indicates carbon atoms of X5P and the lower level indicates carbon atoms of R5P) to products (numbers in the 1st row
reflect carbon atoms of G3P from 1 to 3 and S7P from 1 to 7),
and zero reflects no channeling between particular atoms
in the metabolites. For the transaldolase reaction, S7P ⫹
G3P N E4P ⫹ F6P (E4P is erythrose 4-phosphate and F6P is
fructose 6-phosphate), the corresponding ADM is shown in
Matrix 2. Finally, for the transketolase 2 (TK2) reaction,
X5P ⫹ E4P N G3P ⫹ F6P, the corresponding ADM is shown
in Matrix 3.
We accounted for the reversibility of every reaction by considering forward and reverse reaction steps through the nonoxidative PPP branch with a different extent of reaction reversibility for every reaction above. The system will still result in
constant oxidative PPP net flux for every reaction. Overall,
these matrices show that label at a particular 1st position of
MARCH 4, 2016 • VOLUME 291 • NUMBER 10

pentose 5-phosphate in the oxidative branch will result in the
labeling of all carbon atoms in downstream metabolites such as
pyruvate and lactate.
Metabolic and transport parameters as well as metabolite
pool sizes used here are published elsewhere (36). For other
parameters such as concentrations of the TCA cycle intermediates not reported in this reference, pool sizes were assumed to
be in the range 0.1– 0.2 mM. The total citrate pool size was
assumed to be 0.5 mM with 20% in the mitochondria and 80% in
cytosol. Pyruvate was assumed to be 20% in mitochondria. Sensitivity analysis (not shown here) verified that the chosen TCA
cycle intermediate pool sizes did not affect extracted fluxes
within 5% (even when modified by factors of 5 both above and
below the assumed values).
Minimization of sum-of-squared residuals between simulated and experimental data was performed using BroydenFletcher-Goldfarb-Shanno, Levenberg-Marquardt, or Simplex
algorithms. Proper mean square convergence was confirmed by
verifying that goodness-of-fit values were close to expected theoretical values. The errors of the calculated parameters were
estimated using Monte Carlo simulations with experimental
noise levels (37). All numerical procedures were carried out in
Matlab (Mathworks, Natick, MA).
In this study, LC-MS data have been utilized to compare
fluxes under different conditions (e.g. hyperglycemia versus
euglycemia) without detailed flux analysis (because no statistically significant change was observed between the different
medium glucose conditions).
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The classical PPP consists of two branches, irreversible oxidative and reversible non-oxidative parts. The oxidative branch
represents the net PPP flux and produces NADPH, which
can be used in many reductive synthetic pathways, including
de novo lipogenesis. The PPP reactions are summarized in
the Fig. 2.
To describe the pentose phosphate pathway, we used the
steady-state bonded cumomer flux model variant (which results in a system of non-linear algebraic equations for the (i)
cumomer fraction; see the equation for (i), instead of the set of
differential equations) to fit 13C NMR lactate data acquired
after an 8-h incubation of DB-1 cells with [1,2-13C2]glucose
tracer. The fitted steady-state data were Lac3Tot, Lac2Tot,
Lac3s, Lac3d23, Lac2s, and Lac2d23 multiplets. The relations
between lactate multiplets and bonded cumomers are presented elsewhere (22). Non-oxidative reactions are assumed
to follow carbon atom redistributions (based on the pingpong chemical mechanism) depicted in the following atom
distribution matrices (ADM) (22, 35). Particularly for the
transketolase 1 (TK1) reaction, X5P ⫹ R5P N G3P ⫹ S7P,
where xylulose 5-phosphate (X5P) and ribose 5-phosphate
(R5P) forms glyceraldehyde 3-phosphate (G3P) and sedoheptulose 7-phosphate (S7P), the corresponding ADM is
shown in Matrix 1.
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Results
P NMR—A typical 31P spectrum is shown in Fig. 1B. The
␤-NTP resonance at ⫺16.5 ppm was used to estimate the
cell concentration. Other prominent resonances in the spectrum are ␣- and ␥-NTP, diphosphodiesters, glycerophosphocholine, glycerophosphoethanolamine, inorganic phosphate,
phosphocholine, phosphoethanolamine, and diphosphodiesters, including NADP(H). A broad hump emanating from
immobilized phosphates from lipids dominates the central
region of the spectrum. This broad peak can be removed by
31
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FIGURE 1. Bioreactor design and NMR spectra of DB-1 melanoma cells. A,
schematic drawing of the apparatus used to perfuse cells inside the NMR
spectrometer. Two polarographic oxygen probes are used to continually measure the oxygen consumption rate of the perfused culture. An electrical resistant heater is used to maintain the culture at a constant temperature of 37 °C.
The probes and the recirculated medium are housed in a small incubator (not
shown) to maintain the probes at a constant temperature. A peristaltic pump
is used to circulate the medium. Additional details are available in Ref. 20. B,
31
P NMR spectrum of metabolically active DB-1 cells. The spectrum was
obtained in 20 min. C, 13C NMR spectrum of metabolically active DB-1 cells
during perfusion with medium containing 26 mM [1,6-13C2]glucose at the end
of experiment. Glu, glutamate; Lac, lactate; Glc, glucose; std, ethanol in capillary; FA, –CH2– groups in long chain fatty acids.

off-resonance saturation that is mediated by spin diffusion
through the phospholipid semi-immobilized matrix, but this
might modify resonance intensities of metabolites that are partially or transiently bound to membranes (38). We therefore
have avoided off-resonance saturation. Other methods of
removing the “hump” include fitting it with a spline function
and subtracting the base line or subtracting the first spectrum
and monitoring differences in peak intensities over time (39).
The spectrum in Fig. 1B indicates the energy level of the tumor
cells (measured by the intensity of the ␤-NTP peak). The level
was measured before and after the time course of the 13C NMR
experiment and was unchanged. Usually, the bioenergetic status of the cells is measured by the ␤-NTP/Pi ratio; however, in a
bioreactor the Pi resonance is dominated by the Pi in the perfusate. The latter peak could be removed by applying strong gradients that dephase resonances of flowing metabolites (38, 40),
but we have not applied this method here because it could lead
to errors if removal of mobile resonances was incomplete.
Metabolic Fate of [1,6-13C2]Glucose in DB-1 Cells—Fig. 2
shows the entire metabolic network that is included in the current analysis (see under “Experimental Procedures” for details).
13
C labeling results for DB-1 melanoma cells grown at a constant glucose level of 26 mM are shown in Figs. 1C, 3, and 4. Fig.
1C displays a 13C NMR spectrum that was obtained during the
final 15 min of the experiment. Resonances were detected for
C3 of lactate, C2, C3, and C4 of glutamate, C2 and C3 of aspartate, and fatty acyl carbons. With the glucose concentration
clamped at 26 mM, lactate labeled at C3 (20.9 ppm) appeared in
the spectrum within the first few minutes (Fig. 4A). The level of
this resonance increased throughout the experiment but did
not reach saturation. The time course of the intensity of this
resonance is the combined result of the biological rate of lactate
formation and the rate of washout of lactate due to the continuous addition of fresh medium and withdrawal of spent
medium from the perfusion system. Fifteen minutes after introduction of labeled glucose, 13C incorporation was detected in
C4 of glutamate (34.3 ppm); the full time course for labeling
results for this resonance is shown in Fig. 3. The concentration
increased in a linear manner for approximately 1 h. Subsequently, satellites were observed in this resonance indicating
the presence of 13C-13C coupling between glutamate-C4 and
glutamate-C3 (5). The rate of labeling of glutamate exclusively
on C4 gradually slowed and reached close to steady state after
⬃5 h. The level of glutamate labeled at both C3 and C4 continued to increase steadily throughout the experiment. Fig. 3, A
and B, shows the labeling results for the glutamate-C3 resonance at 28.8 ppm. Over the 1st h, essentially no 13C labeling
was detected in glutamate-C3. Subsequently, 13C labeling of
glutamate-C3 increased linearly but did not reach saturation.
Approximately two-thirds of the C3 glutamate carbon was coupled (predominantly to glutamate-C4). For glutamate-C2, label
also first appeared approximately 1 h after the beginning of the
experiment (Fig. 3, A and B). However, unlike glutamate-C3,
only a singlet was observed for the first 3 h. Subsequently, a
doublet appeared due to the presence of glutamate-C2,3 labeling. Such glutamate would be produced after carbon 1 was
removed from glutamate-C3,4 during the third turn of the TCA
cycle (5).
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Labeling was also observed in long chain fatty acids at ⬃30
ppm, indicating that DB-1 melanoma cells produce lipid de
novo from glucose (see Fig. 4B). This result is consistent with
results for other cancer cell lines grown in culture (19). Small
amounts of labeling were observed in aspartate-C2 and C3. No
label was observed for any carbon of alanine, probably due to
low total concentrations of alanine; this result is unusual
because most cancer cell lines produce 13C-labeled alanine
from glucose (19, 20). Resonances were observed in regions
associated with the glycerol backbone of phospholipids in triglycerides at ⬃65 ppm. This region also contains resonances
associated with glycolytic intermediates.
Quantifying Bionetwork Fluxes—Our biochemical network
model was used to fit 13C NMR DB-1 melanoma data acquired
during continuous perfusion of cells with [1,6-13C2] glucose in
the bioreactor depicted in Fig. 1A. The experimental data from
isotopomer time courses was converted to 13C-metabolite concentration curves (Figs. 3 and 4). Furthermore, to minimize the
bias introduced by using multiplets with low signal to noise
ratio, only those multiplets with end point concentrations
greater than 0.5 mM were used in the fitting procedure. The
remaining experimental multiplets were used as reference
points for visually examining the fit predicted for low intensity
curves to experimental data but not actually calculating the
goodness of fit of these metabolite resonances, whose noise
MARCH 4, 2016 • VOLUME 291 • NUMBER 10

levels were expected to be high (not shown here). To quantify
fluxes in central metabolism, we combined four types of measurements as follows: three sets of time courses of 1) glutamate
isotopomers (multiplets); 2) total lactate-C3 labeling; 3) acyl
groups of fatty acid resonances determined by NMR in situ; and
4) steady-state 13C NMR lactate isotopomers. The fitted time
courses were as follows: Glu4Tot (where Tot is total), Glu4s,
Glu4d34, Glu3Tot, Glu3d, Glu2Tot, Glu2s, Lac3Tot, and acyl
methylene (–(CH2)n–) resonance, yielding a total of nine
curves. Estimation of the model-free parameters was achieved
by fitting labeled patterns of glutamate, lactate, and fatty acid
acyl methylene groups. The extracted flux values are presented
in Table 1 and in the flux map (see Fig. 5). Flux confidence
intervals were calculated by Monte-Carlo simulations (see Fig.
6A, only four fluxes are shown) and are summarized in Table 1.
Quantifying ATP Production Routes—The predicted fluxes
were used to calculate contributions of glycolysis and oxidative
phosphorylation to ATP production. We assumed that the oxidative phosphorylation phosphate to oxygen ratio equals 2.5 for
NADH and 1.5 for FADH2 oxidation. To assess the contribution of glucose, fatty acids (FA) and glucogenic amino acids, and
glutamine to generating reducing power, we calculated the
fluxes for each of these metabolites. For each of the above substrates, we calculated the NADH/FADH2 reaction flux based on
the different labeling patterns that we were able to track both
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 2. Melanoma bionetwork: glycolysis, PPP, TCA cycle, ␣-ketoglutarate-glutamate, and oxaloacetate-aspartate exchange through the
malate-aspartate shuttle, anaplerosis through (a) pyruvate carboxylase activity, (b)succinyl-CoA, and (c) glutaminolysis through mitochondrial glutaminase (GLS and GLS2); pyruvate recycling through cytosolic (ME1) and mitochondrial malic enzymes (ME2 and ME3), lactate
dehydrogenase activity, de novo fatty acid synthesis, and transport processes. The following abbreviations were used for the metabolites of
glycolysis: G6P, glucose 6-phosphate; F6P, fructose 6-phosphate; F16BP, fructose 1,6-bisphosphate; G3P, glyceraldehyde 3-phosphate; PEP, phosphoenolpyruvate. Abbreviations for the oxidative branch of PPP are as follows: 6PG, D-6-phosphogluconate; Ru5P, D-ribulose 5-phosphate. Abbreviations for
the non-oxidative PPP branch are as follows: R5P, D-ribose 5-phosphate; X5P, D-xylulose 5-phosphate; S7P, D-sedoheptulose 7-phosphate; E4P, D-erythrose 4-phosphate.
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from the labeled and unlabeled carbon atoms. The combined
cytosolic ATP production flux was 150 mmol/liter-cell/h, and
the mitochondrial compartment produced 154 mmol/litercell/h due to oxidative phosphorylation. The results are presented in Table 1.
Pentose Phosphate Pathway (PPP)—We fitted 13C NMR
steady-state lactate multiplets acquired after an 8-h incubation
of DB-1 cells with [1,2-13C2]glucose tracer. The experimental
13
C NMR spectra and the results of fitting are shown in the Fig.
7. The extracted fluxes relative to glycolytic flux are presented
in Table 1. Flux standard deviations were calculated by MonteCarlo calculations. Flux through the oxidative PPP was estimated to be 3.6% of the glycolytic rate. Given the extensive
experimental data that have been obtained for the lactate 13C
NMR multiplets, we were also able to estimate non-oxidative
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exchange fluxes (the smaller rates of each reversible reaction) of
the classical PPP (Fig. 2), which are presented in Table 1. Transketolase 1 and transaldolase exchange fluxes in the non-Ox
PPP branch were consequently relatively high at 21 and 44%,
respectively, and transketolase 2 activity was close to zero. The
flux standard deviations (Table 1) demonstrate that all fluxes
through the PPP were resolved but with relatively poor resolution (when using only 13C NMR isotopomers of lactate as a
reporter molecule). NADPH production flux via the oxidative
PPP pathway was estimated to be 6.6 mmol/liter-cell/h. At the
end of this experiment, we measured glucose and lactate concentration in the flask experiments. Glucose concentrations
under euglycemic conditions were unchanged within 30%.
Quantifying Glutaminolysis Flux—Our recent focus has
turned to refinement of the details of glutaminolysis because of
its critical role in the metabolism of many malignancies. For
example, one glutamine molecule could produce up to 22.5
ATP molecules. Therefore, even a small amount of glutaminolysis can have a major effect on the bioenergetics of cancer
cells. In DB-1 melanoma under hyperglycemic conditions, glutamine uptake flux ranged up to 50% of the TCA cycle flux.
VOLUME 291 • NUMBER 10 • MARCH 4, 2016
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FIGURE 3. Time courses for labeling of glutamate during perfusion with
medium containing [1,6-13C2]glucose. A, time course fits for labeling of
glutamate (indicated with “fit” ending) at positions 4, 3, and 2. Glu4, 13C at
glutamate-C4; Glu4s, singlet at glutamate-C4; Glu4d34, doublet at glutamateC4; Glu2, 13C enrichment at glutamate-C2; Glu3, 13C at glutamate-C3. “fit”
ending stands for the model fit and no-ending reflects experimental values. B,
time course for labeling glutamate at positions 2 and 3. Fitted curves labeled
with ending fit are Glu2 and Glu3 total; Glu2s, singlet at glutamate-2; Glu3s,
singlet at glutamate-3; Glu3d, doublet at glutamate-3. PE stands for positional
enrichment; this is predicted mitochondrial enrichment of acetyl-CoA at position C2 and mitochondrial Pyr at position C3 multiplied by a factor of 10.
Curves are fit, and points are experimental data.

FIGURE 4. Experimental data and least squares fit of time course for
labeling of lactate-C3 and fatty acyl methylene (–(CH2)n–) resonance
in proliferating DB-1 melanoma cells during perfusion with medium
containing [1,6-13C2]glucose and unlabeled glutamine. A, time course
for labeling of total lactate-C3 (medium ⫹ intracellular). B, de novo lipogenesis in melanoma cells. Time course for labeling of fatty acyl methylene (–(CH2)n–) resonance.
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TABLE 1
Extracted fluxes using bonded cumomer modeling
Reaction

Fluxa

Pentose phosphate pathway (oxidative branch), net PPP FpppOx
Transketolase 1 (exchange) relative to glycolysis, TK1
Transketolase 2 (exchange) relative to glycolysis, TK2
Transaldolase (exchange) relative to glycolysis, TA
Glucogenic amino acids contribution to pyruvate, FGAA
TCA cycle rate, FTCA (isocitrate 3 ␣-Kg)
Exchange, Mal-Asp shuttle, Fx (reversible)
Pyruvate carboxylase flux, Fpc
Anaplerotic exchange flux at succinyl-CoA, Fxana
Net anaplerotic flux to the TCA cycle, dFana
Flux of ketogenic AA and FA to acetyl-CoA formation, Fkaa
Glutaminolysis flux, Fgls
Pyruvate dehydrogenase flux, Fpdh
Citrate synthase flux, Fcs
Net fumarase activity, Fum 3 Mal, Ffum
Fatty acid synthesis, Ffas
Mitochondrial pyruvate transport, Fmpc
Malic enzyme (mitochondrion), ME2 ⫹ ME3, Fmem
Malic enzyme (cytosolic), ME1, Fmec
Aspartate efflux, dFxasp
Production flux of ATP, glycolytic, Warburg, FatpCyt
Production flux of ATP, mitochondrial, oxphos, FatpOx
Warburg parameter (net LDH/MPC flux ratio)
Combined glycolysis and PPP flux from G6P to pyruvate
Glutamine consumption flux (for protein, nucleotides, amino acids, glutathione, etc.)
Net LDH activity, Pyr 3 Lac, FLDH
Lactate transport, Vmaxlac
Lactate transport, Michaelis-Menten parameter, Km

3.3 ⫾ 72%
21 ⫾ 56%
0.5 ⫾ 90%
44 ⫾ 64%
5.0 ⫾ 20%
10.9 ⫾ 8%
11.3 ⫾ 19%
0.6 ⫾ 51%
3.0 ⫾ 15%
4.3 ⫾ 15%
0.1 ⫾ 19%
0.05 ⫾ 60%
10.8 ⫾ 16%
11.5 ⫾ 14%
15.3 ⫾ 16%
0.59 ⫾ 15%
7.1 ⫾ 23%
4.3 ⫾ 12%
0.6 ⫾ 15%
0.06 ⫾ 45%
150 ⫾ 13%
154 ⫾ 12%
21 ⫾ 24% (unit-less)
152.1 ⫾ 12%
4.9 ⫾ 10%b
150 ⫾ 12%
395 ⫾ 12%
3.5 mM ⫾ 70%

mmol/liter-cell/h

b

Calculated fluxes are expressed in mmol/liter-cell/h with relative standard deviations in percent for pathways shown in Fig. 2. Warburg parameter is the ratio of the net flux
through lactate dehydrogenase (LDH) to the mitochondrial pyruvate carrier influx (MPC).
Standard deviation was estimated based on experimental measurements of glutamine consumption.

FIGURE 5. Metabolic flux map and energy metabolism with predicted oxygen consumption rate MRO2 in the human melanoma DB-1 bionetwork at
hyperglycemia and normoxia. Numbers indicate net fluxes in mmol/liter-cell/h. See Table 1 for definitions and values of the derived fluxes. Reversibility for
SDH, Fumarase, and MDH was taken into account as 10% of the direct flux. Varying the extent of reversibility in the range 5⫺30% does not change extracted
fluxes within several percent (results not shown).

Under euglycemic conditions, glutamine uptake doubled
reaching approximately the same level as TCA cycle flux. Glutamine uptake can lead to protein synthesis, glutathione synthesis, or nucleotide synthesis as well as to ATP production by
the glutaminolysis pathway (see below) or to cytosolic reductive
carboxylation driven by glutaminase 1 (GLS; it is considered
to be present both in mitochondria and cytosol) or other
MARCH 4, 2016 • VOLUME 291 • NUMBER 10

glutamine-glutamate conversion enzymes in cytosol and
isocitrate dehydrogenase 1 (IDH1) (41). It was, therefore,
important to refine the metabolic analysis of DB-1 melanoma to accurately assess the contributions of the glutaminolysis pathway in these tumor cells (see Fig. 2). To quantify
the glutaminolysis contribution to energy production, we
modified the bionetwork by simultaneously allowing net gluJOURNAL OF BIOLOGICAL CHEMISTRY

5165

Downloaded from http://www.jbc.org/ at Thomas Jefferson University on May 18, 2016

a

Cumomer Analysis of Cancer Cell Metabolism

tamine influx into mitochondria through glutaminase 1 and
2 (GLS and GLS2) (Fig. 2).
“Classical” glutaminolysis includes uptake of glutamine by
the cell, transport to mitochondria, conversion to glutamate
through mitochondrial glutaminase 1 or 2 (GLS and GLS2),
entry into the TCA cycle to ␣-ketoglutarate via glutamate
dehydrogenases 1 and 2 (GLUD1 and GLUD2) or via mitochondrial aminotransferases (GPT2 and GOT2), traversing
to oxaloacetate, and exiting as pyruvate or aspartate. Alternatively, glutaminolysis could partially occur in the cytosol
by producing glutamate or ␣-ketoglutarate from glutamine
and eventually by entry of those metabolites into the TCA
cycle as ␣-ketoglutarate. Further flux in the TCA cycle then
moves to malate where malate-pyruvate cycling occurs (Fig. 2).
There are two pathways for pyruvate-malate cycling. One path-
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way involves conversion of malate via mitochondrial malic
enzyme (ME2) to pyruvate; it then returns to oxaloacetate via
pyruvate carboxylase or it can go from pyruvate to acetyl-CoA
leading to citrate. The second pyruvate cycling pathway goes
from malate in the mitochondria through a transporter into the
cytosol and from there to cytosolic pyruvate via cytosolic malic
enzyme (ME1). The cytosolic pyruvate can return to the mitochondria through the mitochondrial pyruvate carrier or it can
be converted to alanine via alanine-aminotransferase (GPT1)
or to lactate via lactate dehydrogenase. The BC approach can
distinguish between these pyruvate-malate pathways or their
combinations under real conditions (Fig. 2).
We continue the analysis of data of DB-1 melanoma cells
treated with [1,6-13C2]glucose as the tracer. Dynamic analysis
indicates that the curves resulting from fitting of the C4-labeled
glutamate multiplets, particularly the glutamate 3,4-doublet,
Glu4d34, resulting from simultaneous labeling of C3 and C4
(during the second TCA cycle turn) and the singlet resulting
from glutamate labeling exclusively at C4 (during the first turn
of the TCA cycle), are very sensitive to flux through the glutaminolysis pathway even when only natural abundance medium-derived glutamine has been used. See for example Fig. 6B,
where the separation and shape of the glutamate C4 total and
the glutamate C4 singlet and 3,4-doublet, Glu4d34, curves
VOLUME 291 • NUMBER 10 • MARCH 4, 2016
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FIGURE 6. Confidence intervals revealing the extracted fluxes and the
sensitivity analysis for glutaminolysis pathway. A, Monte Carlo simulation
of relative standard deviations (Rsd) of parameters estimated in fitting of data
in Fig. 3 to the bonded cumomer model. The experimentally estimated noise
level was 0.2 mmol/liter-cell. For example, relative standard deviation for TCA
cycle flux RsdFtca ⫽ 8% and for pyruvate carboxylase flux RsdFpc ⫽ 51%. See
Table 1 for definitions and values of the derived fluxes. The red line represents
a Gaussian distribution. Only four fluxes are shown. B, sensitivity analysis for
glutaminolysis pathway during perfusion with medium containing [1,613
C2]glucose and unlabeled glutamine. Data show simulated 13C turnover
curves for glutamate C4 (Glu4) and its multiplets 4s and 4d34 for different
values of net glutaminolysis flux Fgls when glutaminolysis is first set to 20% of
the value of the TCA flux (dashed lines) and then to10% of the TCA flux (solid
lines). The glutamate C2 and C3 multiplets were also sensitive (results not
shown). All other fluxes are kept constant. The glutamate doublet 4d34 is the
most sensitive glutamate multiplet to the glutaminolysis net flux.

FIGURE 7. High resolution 13C and 1H NMR spectra of lactate from DB-1
cells incubated with [1,2-13C2]glucose and experimental lactate multiplets versus fit. A, 13C NMR spectra. The left panel shows the NMR spectrum at
the chemical shifts around lactate C2, and the right panel shows the spectrum
around lactate C3. 2s, lactate singlet at C2 position; 2d32, lactate C2 doublet
with carbon coupling between the carbon 2 and 3 positions; 3s, lactate singlet
from the C3 position; 3d23, lactate C3 doublet with carbon coupling between
the carbon 2 and 3 positions. B, proton-observed carbon-edited 1H NMR spectra. The upper panel shows the labeled lactate, and the lower panel shows the
unlabeled lactate. C, experimental multiplet fraction (left bars, black) versus
fitting (right bars, patterned) for lactate C3 and C2, and the predicted lactate
C1 multiplets, based on the evaluated oxidative and non-oxidative branches
of the PPP. Error bars indicate standard deviation. The extracted oxidative PPP
flux and the relative exchange fluxes for transketolases and aldolase are presented in Table 1.
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TABLE 2
Experimental data compared with calculated values determined by
dynamic bonded cumomer modeling
Flux values are in mmol/liter-cell/h, and concentrations are in mM.
Reaction
Oxygen consumption, MRO2
Glucose uptake, MRGlc
LDH activity, Pyr 3 Lac, Fldh
Glutamine uptake, FGln
Glutamate concentration

Experimental
data

Calculated
values

33
90.0
155.0
5.0
8.6c

32
78a
150
–b
9.2

a

The difference between experimental and calculated glucose consumption rates
is due to glycogen production that is not included in the metabolic network
model.
b
The flux was not estimated since glutamine is consumed in numerous reactions
that were not included in the analysis.
c
The glutamate concentration was measured at the end of the bioreactor experiment by cell extraction and LC-MS analysis.

change dramatically when anaplerotic flux from glutamine
increases from 10% of the TCA flux to 20%. This indicates that
glutamate labeling kinetics is sensitive to glutaminolysis flux
and that there is no need to purchase or synthesize exotically
labeled glutamine (with 13C, 15N, or 2H labeling) to evaluate
glutaminolysis.
We then evaluated the contribution of glutaminolysis flux to
overall energy production of DB-1 melanoma cells. We found
that for this tumor line, glutaminolysis flux through the truncated TCA cycle and via pyruvate-malate cycling by malic
enzyme ME2 is essentially zero. This conclusion resulted
directly from the ability of the model to detect glutaminolysis
flux by fitting of data on the glutamate multiplets (see above).
To further confirm this conclusion, we forced the model to
accommodate glutaminolysis flux between 5 and 20% of the
TCA cycle flux. Invariably, this grossly deteriorated the goodness-of-fit of the isotope kinetic data to the model (results not
shown).
Even though glutaminolysis does not contribute to the mitochondrial ATP production, there is still substantial mitochondrial malic enzyme flux (combined activities of NADH producing ME2 and NADPH producing ME3), which is equal to ⬃40%
of the TCA flux (see Table 1).
Effect of Hyperglycemia/Euglycemia on Glutamine and Fatty
Acid Metabolism—The mass isotopomer distribution of several
TCA cycle metabolites from [U-13C5,15N2]glutamine labeling
experiments is shown in Fig. 8 at different glucose concentrations in the medium, at 5 mM for euglycemia and 25 mM for
hyperglycemia. With this tracer, increased glutaminolysis flux
resulted in increased abundance of the M ⫹ 4 mass isotopomer
MARCH 4, 2016 • VOLUME 291 • NUMBER 10
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FIGURE 8. Mass isotopomer distribution for the TCA cycle intermediate
and acetyl-CoA measured at hyperglycemic and euglycemic conditions
during [U-13C5]glutamine labeling. Mass isotopomer distribution (MID) of
A, citrate; B, malate; C, succinate; and D, acetyl-CoA. The figure clearly demonstrates that there are no significant differences in labeling patterns of key
metabolites (p value was always ⬎0.05) between 5 mM glucose and 25 mM
medium glucose conditions.

of citrate, succinate, and malate (41), whereas reductive carboxylation resulted in increased M ⫹ 3 for malate, M ⫹ 4 for succinate, and M ⫹ 5 for citrate. Reductive carboxylation and
increased glucose contribution to the fatty acid production also
disturbs the acetyl-CoA mass isotopomer distribution. Fig. 8
clearly shows that there are no significant differences in labeling patterns of all four metabolites. Consequently, based on
bioreactor data, we can exclude any major change in glutaminolysis flux as well as for fatty acid production under hyperglycemic versus euglycemic conditions.
Quantifying de Novo Lipogenesis Flux in DB-1 Cells—During
culturing of DB-1 cells with [1,6-13C2]glucose, progressive
labeling of fatty acids was observed for multiple resonances (see
Figs. 1C and 4B). FA synthesis occurs first by cytosolic citrate
production from glucose and through reductive carboxylation
in the cytosol from glutamine through isocitrate dehydrogenase (IDH1 isoform). By ATP citrate lyase, cytosolic citrate is
converted to oxaloacetate and cytosolic acetyl-CoA, which is
converted further to malonyl-CoA by the rate-limiting acetylCoA carboxylase (ACC-␤) and through fatty acid synthases to
elongated precursors via sequential addition of acetyl-CoA,
eventually leading to palmitate production. Palmitate is further elongated or desaturated to produce numerous other
FAs. To address de novo FA flux production, we utilized the
BC model with cytosolic FA and their precursors as well as
membrane fatty acids as the second FA pool. We calculated
FA content based on the total FA content of ⬃20% of cell dry
weight of 200 mg/109 cells (5 ⫻ 108 cells ⫽ 1 ml). Total FA
content referenced to palmitate is at the level of several tens
of mmol/liter-cell. We iteratively varied the ratio of cytosolic
to membrane FA and found the best fit at ⬃10 times more FA
in the cytosolic membrane compartment (Fig. 4B). The de
novo flux of conversion of glucose to FA was 0.59 mmol/litercell/h, and NADPH consumption flux in FA biosynthesis was
8.4 mmol/liter-cell/h.
Model Validation—As validation of the inferred/extracted
fluxes, we measured the MRO2 with polarographic oxygen
probes during the perfusion experiment. The fluxes obtained
by fitting of dynamic 13C data produced good agreement
between the experimentally observed MRO2, 33 mmol/litercell/h, and the calculated MRO2, 32 mmol/liter-cell/h (see
Table 2). The experimental total glutamate concentration was
8.6 mM. Assuming the glutamate concentration to be a fitted
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TABLE 3
Experimental glucose and glutamine consumption fluxes under
euglycemic (6.4 mM) and hyperglycemic conditions (23.2 mM in
medium)

TABLE 4
Experimental medium glucose and lactate concentrations under
euglycemic (5.1 mM glucose in medium) and hyperglycemic conditions (25.0 mM) after 8-h incubation

Glutamine ⫽ 3.0 mM at low glucose and 3.4 mM at high glucose. FGlc, glucose consumption flux (mmol/109cells/h) and FGln, glutamine consumption (mmol/109cells/h). Flux
ratios were FGlc/FGln ⫽ 22.4 at high glucose and FGlc/FGln ⫽ 13.5 at euglycemia.

Euglycemia (6.4 mM)
Hyperglycemia (23.2 mM)

Glutamine
flux

Glucose
flux

0.064
0.035

0.86
0.79

Discussion
Measuring the relative glycolytic and oxidative capacity of
specific tumors plays an important role in development of strategies for treating neoplasms and for monitoring tumor response to specific therapeutic agents. For this reason, development of a non-invasive method for quantifying the fraction of
ATP production by tumors that occurs by glycolytic and
mitochondrial metabolism would be useful in the management of cancer and tailor-fitting of therapeutic regimens to
the needs of individual patients. In addition, various other
pathways of tumor metabolism play critical roles in tumor
proliferation by providing additional energy sources and
essential precursors for cell replication. Our goal was to
develop a method for quantitating tumor intermediary
metabolism in cells and with some extension in animal
tumor models and human cancer patients.
One of our key objectives was to validate the bonded
cumomer modeling technique as a method for measuring
fluxes through key pathways of tumor energy production. This
is best accomplished by comparing model predicted parameters with independently measured experimental parameters as
has been demonstrated previously by Chatham et al. (6) for the
cardiac TCA cycle model of Chance et al. (5) and Jeffrey et al. (7)
for the isotopomer model of the heart. Table 2 compares mod-
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Lactate
concentrationa

Euglycemia (5.1 mM)

3.6 ⫾ 0.1

5.0 ⫾ 0.2

Hyperglycemia (25.0 mM)

23.4 ⫾ 0.1

5.5 ⫾ 0.3

Initial medium lactate concentration was 1.8 mM for euglycemic conditions and
2.0 mM for hyperglycemia.

el-predicted and experimentally measured parameters. There
is excellent agreement between the predicted MRO2 (32 mmol/
liter-cell/h) and the experimentally measured rate of oxygen
consumption (36 mmol/liter-cell/h). The experimental and
predicted rates of glucose uptake agree within 7%. The experimental and predicted pyruvate to lactate fluxes, 149 and 150,
respectively, agree within ⬃1% and glutamate pool sizes within
7%. Overall, this excellent agreement between model-predicted
and experimental data validates the BC model.
ATP production fluxes were calculated assuming a phosphate to oxygen ratio of 2.5 for NADH and 1.5 for FADH2 (42).
Under hyperglycemic conditions, the average ATP production
rates were MRATP (mitochondrial) ⫽ 154 mmol/liter-cell/h
and MRATP (glycolytic) ⫽ 150 mmol/liter-cell/h which indicates that 51% of the energy was produced by oxidative phosphorylation and 49% was from glycolysis. Based on the similarity of isotopomer labeling patterns under hyperglycemic and
euglycemic conditions (Fig. 8), we expect no significant change
in glycolytic and oxidative metabolism under these conditions.
High fluxes of pyruvate mitochondrial transport (⬃70% of the
TCA cycle activity) and mitochondrial ATP production are
promoted by the melanoma-associated BRAF mutation. Recent
work (43) has demonstrated that BRAF V600E mutated melanoma cells exhibit increased pyruvate entry through the activated PDH complex. PDH flux (⬃106% of the TCA flux) is
regulated by inhibitory phosphorylation mediated by PDH
kinases (PDK) and PDH phosphatases (PDP). The oncogene
BRAF V600E causes concerted activation of the PDH complex
by down-regulation of PDK1 expression and up-regulation of
PDP2 thereby promoting oxidative pyruvate utilization and
leading to increased cellular respiration.
There has been considerable interest in glutamine metabolism as a key source of tumor energy production linked to
c-Myc expression (21, 44 – 47). Our model of tumor metabolism (Fig. 2) contains a specific glutamine transporter on the cell
membrane. The classical model of glutaminolysis includes an
additional specific glutamine transporter on the mitochondrial
membrane that leads to mitochondrial glutaminase (GLS2 or
GLS), which converts glutamine to glutamate, which is then
converted to ␣-ketoglutarate by enzymes such as glutamate dehydrogenase (GLUD1 and -2). Two additional transaminases
can carry out the glutamate–␣-ketoglutarate exchange, aspartate aminotransferase, and alanine aminotransferase. The ␣ketoglutarate then produces reducing equivalents via the oxidative branch of the TCA cycle leading to ATP production by
oxidative phosphorylation. Various pathways, including the
malate-aspartate shuttle, pyruvate carboxylase, malic enzyme,
and phosphoenolpyruvate carboxykinase (PEPCK1 and -2) all
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parameter, we calculated this parameter and obtained a value of
9.2 mM in good agreement with the experimental concentration. The measured glucose consumption rate (MRGlc) was 90
mmol/liter-cell/h, whereas the predicted MRGlc was 78 mmol/
liter-cell/h. Simultaneously, the measured lactate production
flux (MRlac) was 155 mmol/liter-cell/h, whereas the predicted
MRlac was 150. We note that we did not use experimentally
measured fluxes as constraints in our bonded cumomer metabolic flux analysis.
Table 3 compares glucose and glutamine uptake under euglycemic (6 mM glucose) and hyperglycemic (23 mM) conditions.
Under euglycemic conditions, glutamine influx approximately
doubles, whereas glucose consumption remains essentially
unchanged. Table 4 shows the glucose and lactate concentrations at the end of experiments at different glycemic conditions
conducted in the flask experiments for mass spectrometric measurements. Glucose concentrations were unchanged within
30% under euglycemic conditions and within 5% under hyperglycemic conditions. Finally, we were able to generate a flux
map (Fig. 5). This figure shows the extracted metabolic fluxes
with the predicted MRO2. Numbers indicate fluxes in mmol/
liter-cell/h. See Table 1 for definitions and values of the derived
fluxes.

a

Glucose
concentration
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tamate without any net flux. In addition, glutamine could be
used for many other metabolic processes besides energy production, e.g. protein, nucleotide, and hexosamine synthesis.
If the net uptake of glutamine is 5 mmol/liter-cell/h with
negligible contribution to energy production, glutamine must
be contributing primarily to anabolic processes such as amino
acid, nucleotide, and protein production as well as to de novo
lipogenesis. Although glutamine-derived carbons have been
unlabeled, we have monitored lipogenesis by 13C NMR
detecting methylene carbon acyl groups originating from
labeled glucose (Figs. 1C and 4B). Table 1 indicates that de
novo lipogenesis corresponds to ⬃6% of the TCA cycle flux
under hyperglycemic conditions. However, this does not
include possible direct contributions from unlabeled glutamine (i.e. through cytosolic reductive carboxylation by isocitrate dehydrogenase IDH1 or mitochondrial IDH2) and
potentially from the cytosolic acetyl-CoA synthetase 2
(ACSS2) reaction (50).
This modest flux for de novo fatty acid synthesis requires a
large contribution of NADPH cofactor production (⬃8.3
mmol/liter-cell/h). NADPH could be produced by the oxidative
branch of the PPP, malic enzyme, or isocitrate dehydrogenase
activities or by serine-glycine one-carbon metabolism (folate
metabolism). Our calculated malic enzyme activities in mitochondria (even if all this activity is represented by ME3) would
account for 4.3 mmol/liter-cell/h, and cytosolic NADPH flux
(ME1, 0.6 mmol/liter-cell/h) would not account for the
required high level of NADPH flux. A recent elegant study (51)
suggested that in some cancers folate metabolism is the largest
source of NADPH. Based on these data (52), we estimated that
the serine-glycine one-carbon metabolism pathway cannot
account for the required NADPH consumption. In the light of
our 13C NMR lactate labeling data, the oxidative branch of the
PPP is the main source of NADPH in these cancer cells (6.6
mmol/liter-cell/h). This constitutes ⬃80% in agreement with
the NADPH consumption rate during fatty acid biosynthesis.
Thus, the flux through the oxidative PPP appears to be ⬃80%
sufficient to supply all of the NADPH required for fatty acid
production and is the main supplier of reducing equivalents in
DB-1 melanoma. A 20% difference in the rates of NADPH production and consumption indicates that alternative sources of
NADP⫹ reduction, considered above, need to be taken into
account. We also found that mitochondrial pyruvate-malate
cycling was very high (4.3 mmol/liter-cell/h). This could also
contribute to defense against reactive oxygen species by producing sufficient NADPH via ME3.
In summary, we have validated a novel method, bonded
cumomer analysis, for determining fluxes through specific
pathways of tumor energy metabolism. This method can be
applied to studies of perfused tumor cells in bioreactors or, with
some modifications, to in vivo studies for non-invasive investigation of the metabolism of tumors in animals or humans. The
transition from isolated cells to in vivo rodent models and
humans is not simple and seamless, but it is feasible. The interested reader experienced in metabolic modeling might pursue
similar objectives using the methods outlined in this study
together with mathematical methods and metabolic models
referenced herein (53).
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contribute to metabolism of the glutamine carbon atoms. As
noted previously, glutamine metabolism can lead to production
of 22.5 molecules of ATP per glutamine molecule. In the case of
DB-1 melanoma cells under hyperglycemic conditions, glutamine influx constituted about 50% of the TCA cycle flux, with
about double this level of glutamine uptake under euglycemic
conditions (Table 3). However, the transaminase reactions are
reversible and may exhibit high exchange flux in both directions even with very little net glutamine uptake by the TCA
cycle and nearly no energy production from the glutaminolysis
pathway in DB-1 cells. It is important to note that because carbon atoms of glutamate originating from glucose will be isotopically labeled (first on C4 position and then on C2 and C3 etc.),
whereas carbons coming from glutamine will be unlabeled, it
was possible to distinguish the two pools of carbon atoms originating from these two substrates. The data fitting clearly indicated that the net flux from glutamine being metabolized via
the TCA cycle was very small.
We also conducted a sensitivity analysis to show that using
[1,6-13C2]glucose tracer alone suffices to reliably calculate
glutaminolysis flux in malignant cells and tissues. Fig. 6B
shows that the glutamate C4 doublets due to C3-C4 coupling
(Glu4d34) are sensitive to net flux of unlabeled glutamine
entering the TCA cycle; even a 10% difference in flux produces
a clearly detectable shift in these curves. Fitting analysis indicated that there was little net influx from glutamine into the
TCA cycle. Note also that this conclusion can also be reached
from 13C NMR data without the use of labeled glutamine.
By contrast, some investigators utilizing mass spectrometry
have equated glutamine uptake minus glutamate release with
net glutaminolysis flux (48). In this case, the net influx of glutamine is ⬃5 mmol/liter-cell/h, which, if it were equated with
glutaminolysis flux, would have been interpreted as 113 mmol/
liter-cell/h of ATP per h or about 75% of the glycolytic production of ATP. Under euglycemic conditions, which produce
about twice the level of glutamine uptake, such an analysis
would have attributed about 50% higher ATP production to
glutaminolysis than to glycolysis, and most of the tumor energy
production would have been attributed to glutaminolysis. This
is incorrect in our case; in reality the net glutaminolysis flux
under hyperglycemic conditions is ⬃0.1 mmol/liter-cell/h or
⬃2 mmol of ATP/liter-cell/h or ⬃1% of the glycolytic ATP
production rate. Bonded cumomer analysis provides a method
for making this crucial distinction. Our labeled LC-MS data for
the TCA cycle intermediates with [U-13C5,U-15N2] glutamine
confirmed that no glutaminolysis occurred under euglycemic
conditions versus hyperglycemia (Fig. 8). The absence of change
in glutaminolysis or reductive carboxylation flux is evident
from similar mass isotopomer distributions of several key
metabolites. Our finding of nearly zero glutaminolysis flux contradicts Scott et al. (49), who, on the basis of glutamine uptake
and label appearance in some TCA cycle metabolites, concluded that glutamine was utilized as an anaplerotic substrate
of several human melanoma lines. However, these authors did
not conduct a rigorous metabolic modeling analysis to measure
flux through the TCA cycle. Consequently, they were unable to
distinguish between actual flux through the cycle via glutaminolysis and exchange labeling between ␣-ketoglutarate and glu-
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